<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04874155</url>
  </required_header>
  <id_info>
    <org_study_id>CT-04</org_study_id>
    <nct_id>NCT04874155</nct_id>
  </id_info>
  <brief_title>Noninvasive Peripheral Nerve Stimulation for Medication-Refractory Primary RLS (The RESTFUL Study)</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Sham-Controlled Study to Evaluate the NTX100 Neuromodulation System for Patients With Medication-Refractory Primary Restless Legs Syndrome (RLS) - The RESTFUL Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Noctrix Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Noctrix Health, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, prospective double-blind randomized controlled pivotal study of noninvasive&#xD;
      peripheral nerve stimulation (NPNS) with the NTX100 Neuromodulation System for patients with&#xD;
      medication-refractory moderate-severe primary RLS&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of a series of two 4-week phases:&#xD;
&#xD;
      Phase 1: Prospective, double-blinded, 1:1 randomized (Active treatment: Sham control)&#xD;
&#xD;
      Phase 2: Prospective, non-randomized, non-blinded, Active treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Study consists of two phases. Phase 1: Randomized 1:1 between Active treatment and Sham control Phase 2: Non-randomized, Active treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Responder rate on Clinical Global Impressions-Improvement (CGI-I) scale</measure>
    <time_frame>Week 4 of each intervention relative to baseline</time_frame>
    <description>Responder rate is defined as the proportion of responses of &quot;Much Improved&quot; or &quot;Very Much Improved&quot; relative to baseline on the investigator-rated 7-point CGI-I scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responder rate on Patient Global Impressions-Improvement (PGI-I) scale</measure>
    <time_frame>Week 4 of each intervention relative to baseline</time_frame>
    <description>Responder rate is defined as the proportion of responses of &quot;Much Improved&quot; or &quot;Very Much Improved&quot; relative to baseline on the participant-rated 7-point PGI-I scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean International Restless Legs Syndrome Study Group Rating Scale (IRLS) score</measure>
    <time_frame>Week 4 of each intervention compared to baseline</time_frame>
    <description>IRLS is a participant-rated questionnaire that rates RLS severity from 0-40, where 40 is the most severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Medical Outcomes Study Sleep Problems Index II (MOS-II) score</measure>
    <time_frame>Week 4 of each intervention compared to baseline</time_frame>
    <description>MOS-II is a subscale of the participant-rated MOS questionnaire that measures subjective sleep quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Medical Outcomes Study Sleep Problems Index I (MOS-I) score</measure>
    <time_frame>Week 4 of each intervention compared to baseline</time_frame>
    <description>MOS-I is a subscale of the participant-rated MOS questionnaire that measures subjective sleep quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Clinical Global Impressions-Improvement (CGI-I) scale rating</measure>
    <time_frame>Week 4 of each intervention relative to baseline</time_frame>
    <description>Mean rating on the investigator-rated 7-point CGI-I scale, where lower scores indicate improvement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Restless Legs Syndrome</condition>
  <arm_group>
    <arm_group_label>Active neurostimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Noninvasive peripheral nerve stimulation device programmed to deliver active stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham neurostimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Noninvasive peripheral nerve stimulation device programmed to deliver non-therapeutic (sham) stimulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NTX100 Neuromodulation System - Active</intervention_name>
    <description>Noninvasive peripheral nerve stimulation device programmed to active mode.</description>
    <arm_group_label>Active neurostimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NTX100 Neuromodulation System - Sham</intervention_name>
    <description>Noninvasive peripheral nerve stimulation device programmed to sham mode.</description>
    <arm_group_label>Sham neurostimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has received a medical diagnosis of primary restless legs syndrome (RLS).&#xD;
&#xD;
          2. Subject is refractory to RLS medication (as defined in section 7.3).&#xD;
&#xD;
          3. Subject has moderate-severe RLS symptoms as defined by a score of 15 or greater points&#xD;
             on IRLS (International Restless Legs Syndrome Study Group Rating Scale [12]) over the&#xD;
             week prior to study entry.&#xD;
&#xD;
          4. Subject has RLS symptoms 2 or more nights per week during the week prior to study&#xD;
             entry as defined by a score of 2, 3, or 4 on IRLS question #7.&#xD;
&#xD;
          5. RLS symptoms are most significant in the subject's lower legs and/or feet.&#xD;
&#xD;
          6. RLS symptoms are most significant at bedtime, after bedtime, and/or in the 2 hours&#xD;
             before bedtime.&#xD;
&#xD;
          7. RLS symptoms between 10am and 6pm are not severe.&#xD;
&#xD;
          8. Subject agrees to not change dosage or schedule of any medications that are known to&#xD;
             impact RLS symptoms during the study, including RLS medications, antidepressants,&#xD;
             sleep medications, or sedative antihistamines.&#xD;
&#xD;
          9. Subject agrees to not make major lifestyle changes during the study including diet,&#xD;
             exercise, career, or other changes that would affect bedtime.&#xD;
&#xD;
         10. Subject possesses the necessary equipment, internet/phone accessibility, and&#xD;
             communication ability to complete electronic questionnaires and respond to electronic&#xD;
             communications and phone calls from the research staff throughout the in-home portion&#xD;
             of the study.&#xD;
&#xD;
         11. Subject is ≥ 22 and ≤ 79 years of age when written informed consent is obtained.&#xD;
&#xD;
         12. Subject has signed a valid, IRB-approved informed consent form, can understand the&#xD;
             requirements of the study and instructions for device usage, and can converse in&#xD;
             English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has RLS that is known to be caused by another diagnosed condition (i.e.&#xD;
             secondary RLS).&#xD;
&#xD;
          2. Subject is taking an unstable or inconsistent dose or schedule of medication that is&#xD;
             likely to impact RLS symptoms, such as antidepressants, sleep medications, or sedative&#xD;
             antihistamines or has changed dosage within the past 30 days.&#xD;
&#xD;
          3. Subject has changed dose and schedule of RLS medications within the month prior to&#xD;
             study entry or is otherwise on an inconsistent dose or schedule of RLS medications.&#xD;
&#xD;
          4. Subject reports having significant prior experience with neurostimulation devices&#xD;
             (including but not limited to TENS devices) or subject has prior experience with&#xD;
             neurostimulation devices developed by the study sponsor.&#xD;
&#xD;
          5. Subject was misdiagnosed with RLS, as determined by the investigator (e.g. actual&#xD;
             diagnosis of PLMD, arthritis, leg spasms or neuropathy without comorbid RLS).&#xD;
&#xD;
          6. Subject has a sleep disorder other than RLS that interferes with sleep at the present&#xD;
             time (except for obstructive sleep apnea that is stably controlled via CPAP).&#xD;
&#xD;
          7. Subject has active medical device implant anywhere in the body (including but not&#xD;
             limited to pacemakers, spinal cord stimulators, deep brain stimulators) or metal&#xD;
             implant in the leg.&#xD;
&#xD;
          8. Subject has failed a nerve conduction study prescribed by a physician or has been&#xD;
             diagnosed with severe peripheral neuropathy.&#xD;
&#xD;
          9. Subject reports that bedtime is typically outside of 9pm-3am or reports that bedtime&#xD;
             regularly varies by more than 4 hours, such as due to shift work.&#xD;
&#xD;
         10. On nights with no RLS symptoms (if any), subject reports typical sleep onset latency&#xD;
             of &gt;60min.&#xD;
&#xD;
         11. Subject has been diagnosed with one of the following conditions:&#xD;
&#xD;
               -  Epilepsy or other seizure disorder&#xD;
&#xD;
               -  Current, active or acute or chronic infection other than common cold&#xD;
&#xD;
               -  A malignancy within the past 5 years (not including basal or squamous cell skin&#xD;
                  cancer)&#xD;
&#xD;
               -  Stage 4-5 chronic kidney disease or renal failure&#xD;
&#xD;
               -  Severe movement disorder symptoms (Parkinson's disease, Huntington's disease,&#xD;
                  dyskinesia, dystonia)&#xD;
&#xD;
               -  Deep vein thrombosis&#xD;
&#xD;
               -  Multiple sclerosis&#xD;
&#xD;
         12. Subject has moderate or severe cognitive disorder or mental illness.&#xD;
&#xD;
         13. Subject has current diagnosis of iron-deficient anemia or history of iron-deficient&#xD;
             anemia within the past year.&#xD;
&#xD;
         14. Subject has known allergy to device materials, electrode gel, polyurethane foam, or&#xD;
             lycra (or severe previous reaction to medical adhesives or bandages).&#xD;
&#xD;
         15. Subject has severe edema affecting lower legs.&#xD;
&#xD;
         16. Subject has any of the following at or near the location of device application.&#xD;
&#xD;
               -  Acute injury&#xD;
&#xD;
               -  Cellulitis&#xD;
&#xD;
               -  Open sores&#xD;
&#xD;
               -  Other skin condition&#xD;
&#xD;
         17. Subject is on dialysis or anticipated to start dialysis while participating in the&#xD;
             study.&#xD;
&#xD;
         18. During the NTX100 calibration process, which is identical for subjects in the active&#xD;
             and sham arms, subject reports not feeling stimulation sensations up to an intensity&#xD;
             of 30mA or finds stimulation intensities less than 15 mA to be uncomfortable or&#xD;
             distracting.&#xD;
&#xD;
         19. Subject has received another investigational device or drug within 30 days before&#xD;
             study entry, is planning to receive another investigational device or drug during the&#xD;
             study, or is planning to change RLS medications during the study.&#xD;
&#xD;
         20. Subject has undergone a major surgery (excluding dental work) in the 30 days prior to&#xD;
             study entry.&#xD;
&#xD;
         21. Subject is unable or unwilling to comply with study requirements.&#xD;
&#xD;
         22. Subject is pregnant or trying to become pregnant.&#xD;
&#xD;
         23. Subject has a medical condition not listed above that may affect validity of the study&#xD;
             as determined by the investigator.&#xD;
&#xD;
         24. Subject has a medical condition not listed above that may put the subject at risk as&#xD;
             determined by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan D Charlesworth, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Noctrix Health, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan D Charlesworth, PhD</last_name>
    <phone>8046834279</phone>
    <email>jcharlesworth@noctrixhealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>California Center for Sleep Disorders</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94578</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahi Yousefian</last_name>
      <email>myousefian@sleepdx.com</email>
    </contact>
    <investigator>
      <last_name>Jerry Kram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Delta Waves, Inc.</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>95125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve Li</last_name>
      <phone>719-262-9283</phone>
      <email>sli@deltawaves.org</email>
    </contact>
    <investigator>
      <last_name>H. Samuel Scheuller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurotrials Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronna Harris</last_name>
      <email>rharris@neurotrials.com</email>
    </contact>
    <investigator>
      <last_name>Russell Rosenberg, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clayton Sleep Institute</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Uhles</last_name>
      <email>UhlesM@claytonsleep.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Ojile, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio Sleep Medicine Institute</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Chen</last_name>
      <email>echen@sleepmedicine.com</email>
    </contact>
    <investigator>
      <last_name>Asim Roy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bogan Sleep Consultants, LLC</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Bowyer, MS</last_name>
      <email>Kim.Bowyer@bogansleep.com</email>
    </contact>
    <investigator>
      <last_name>Richard Bogan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Neurology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Ford</last_name>
      <email>kevinf@fstrials.com</email>
    </contact>
    <investigator>
      <last_name>John Hudson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

